Comparing of Vaccinex Inc. (VCNX) and Agios Pharmaceuticals Inc. (NASDAQ:AGIO)

Vaccinex Inc. (NASDAQ:VCNX) and Agios Pharmaceuticals Inc. (NASDAQ:AGIO), both competing one another are Biotechnology companies. We will compare their risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Vaccinex Inc. 6 173.70 N/A -2.68 0.00
Agios Pharmaceuticals Inc. 51 21.81 N/A -5.99 0.00

Table 1 demonstrates Vaccinex Inc. and Agios Pharmaceuticals Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows the return on assets, return on equity and net margins of the two firms.

Net Margins Return on Equity Return on Assets
Vaccinex Inc. 0.00% 0% 0%
Agios Pharmaceuticals Inc. 0.00% -48.2% -38.6%

Liquidity

The Current Ratio of Vaccinex Inc. is 1.8 while its Quick Ratio stands at 1.8. The Current Ratio of rival Agios Pharmaceuticals Inc. is 6.9 and its Quick Ratio is has 6.9. Agios Pharmaceuticals Inc. is better equipped to clear short and long-term obligations than Vaccinex Inc.

Analyst Recommendations

Vaccinex Inc. and Agios Pharmaceuticals Inc. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Vaccinex Inc. 0 0 0 0.00
Agios Pharmaceuticals Inc. 0 0 1 3.00

Competitively Agios Pharmaceuticals Inc. has a consensus price target of $45, with potential upside of 19.24%.

Insider and Institutional Ownership

Institutional investors owned 1.6% of Vaccinex Inc. shares and 0% of Agios Pharmaceuticals Inc. shares. Vaccinex Inc.’s share owned by insiders are 5.6%. Insiders Comparatively, owned 0.3% of Agios Pharmaceuticals Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Vaccinex Inc. 12.47% -16.36% -25.93% -11.37% 0% 26.21%
Agios Pharmaceuticals Inc. 2.49% -2.96% -9.55% -6.82% -43.99% 4.34%

For the past year Vaccinex Inc.’s stock price has bigger growth than Agios Pharmaceuticals Inc.

Summary

Vaccinex Inc. beats Agios Pharmaceuticals Inc. on 5 of the 8 factors.

Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is VX15 that is in Phase Ib/II clinical trials for the treatment of advanced solid tumors, including non-small cell lung cancer, osteosarcoma, and melanoma; and Phase II clinical trials for the treatment of Huntington's disease. The company's preclinical development products include VX5, a human antibody to CXCL13, a molecule that regulates the formation of immune tissues, for the treatment of MS and other autoimmune disorders; and VX25 is an investigational and bi-specific molecule for the therapeutic application of Natural Killer T cell stimulation for cancer immunotherapy. Vaccinex, Inc. was founded in 2001 and is headquartered in Rochester, New York.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. The company is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients. In addition, it is developing AG-881, a pan-IDH mutant inhibitor that is in Phase 1 clinical trials for the treatment of hematologic malignancies and solid tumors; and AG-348, a small molecule potent activator that is in Phase 2 clinical trial for the treatment of pyruvate kinase deficiency. It has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; and Celgene International II Sarl to develop and commercialize AG-881 products. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.